Skip to main content

Table 8 Estimated market share (%) of biologic agents for the treatment of moderate to severe psoriasis

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent

Base year

Year 1

Year 2

Year 3

Year 4

Year 5

Adalimumab

30

27

25

24

23

23

Etanercept

45

42

39

37

36

35

Infliximab

25

22

20

18

17

16

Ustekinumab

0

9

16

21

24

26